Abcuro will take an anti-KLRG1 antibody into the clinic with new funding... Abcuro will take an anti-KLRG1 antibody into the clinic with new funding, and has big plans for another. A little over two years after pu...
Scorpion Therapeutics strikes major $162M funding round for 'precision oncology 2.0' Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round...
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparat LYON, France and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeuti...
ZielBio Appoints Dieter Weinand Executive Chair CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--ZielBio, Inc., an early-stage biotechnology company discovering new treatments for cancer and othe...
Amolyt Pharma Announces Research Collaboration with PeptiDream Amolyt and Peptidream will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical de...
